newsfilter
← Latest News
GlobeNewswire·

Avalo Therapeutics to Participate in Upcoming Investor Conferences

  • Avalo Therapeutics announced management participation in four investor conferences scheduled for November & December 2025.
  • The company will present at the Guggenheim Second Annual Healthcare Innovation Conference on November 10, 2025, at 4:00 pm ET.
  • Avalo will attend the Stifel 2025 Healthcare Conference on November 12, 2025, at 2:40 pm ET.
  • The firm will participate in the TD Cowen 1st Immunology & Inflammation Summit on November 13, 2025, at 9:00 am ET.
  • Avalo is scheduled to present at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, at 10:30 am ET.
  • Live webcasts & replays will be accessible via the "News / Events" section of the investor relations website at ir.avalotx.com.
  • Archived webcasts will remain available for replay for at least 30 days.
  • Avalo Therapeutics is a clinical stage biotechnology company developing IL-1β-based treatments for immune-mediated inflammatory diseases.
  • Lead asset AVTX-009 is currently in a Phase 2 clinical trial for hidradenitis suppurativa (HS).
  • AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) to neutralize its activity.
  • Christopher Sullivan serves as CFO & primary contact for media & investor inquiries.